1. In Vivo
  2. >>Business Strategy

Pfizer Sets New Biotech M&A Record

Pfizer's proposed acquisition of Rinat Neuroscience is the costliest private biotech purchase yet--it paid $500 million in cash for the CNS play. What's more extraordinary still is that the most valuable asset at Rinat is pre-clinical.

Pfizer Inc. 's proposed acquisition of Rinat Neuroscience Corp. is the costliest private biotech purchase yet. [See Deal] According to Windhover's Strategic Intelligence Systems, Big Pharma paid $500 million in cash for the CNS play--nearly 60% more than the previous record, also held by Pfizer, when it paid $298 million cash for Idun just over a year ago. [See Deal] What's more extraordinary still is that the most valuable asset at Rinat—the one that pushed competitive bidding to the heights it reached—is preclinical. To over-simplify somewhat: Pfizer has paid half-a-billion dollars for a preclinical compound which, according to standard industry attrition rates, has about a 16% chance of even getting to an FDA approval filing.

Well, maybe it's not quite that risky: the compound in question is a humanized monoclonal antibody, RN1215, which targets the...

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.